logo
Private Equity Firms Celebrate Trump's Executive Order Giving Them The Keys To Retirement

Private Equity Firms Celebrate Trump's Executive Order Giving Them The Keys To Retirement

Forbes2 days ago
Donald Trump directed his Secretary of Labor Thursday to reevaluate past guidance on 401(k) regulation in a win for private equity that could unlock trillions in assets. Getty Images
President Donald Trump signed his long-awaited executive order paving the way for 401(k) providers to offer access to private equity investments on Thursday, opening the floodgates to what the private equity industry has long salivated over, as a huge untapped reserve of funds.
With $12.2 trillion in defined contribution workplace accounts like 401(k)s and another $16.8 trillion in individual retirement accounts, according to the Investment Company Institute, individuals' retirement savings could prove spectacularly fruitful for Wall Street if even a small amount of them are allocated to private equity and credit. But these and other alternative assets typically come with higher fees, and plan administrators and sponsors (meaning employers) have been concerned courts could rule that they are breaching their fiduciary obligations under the Employee Retirement Income Security Act of 1974 by offering these products.
'The challenge that has slowed adoption in defined contribution has really been from a litigation standpoint—plan sponsors are reluctant to make available investments that include private markets for fear of being sued,' says Dan Cahill, head of U.S. defined contribution at Swiss-based private equity firm Partners Group. 'It will be on the Secretary of Labor to understand how we can stifle that litigation to allow for innovation to occur.'
Thursday's executive order aims to provide legal cover to sponsors, asking the Secretary of Labor, Lori Chavez-DeRemer, to review and consider rescinding guidance issued by President Joe Biden's labor department that was read as discouraging the prospect of private assets in 401(k)s. The order also covers other alternative asset classes like real estate and cryptocurrencies. It doesn't put any policy into effect immediately and simply asks Chavez-DeRemer to clarify this guidance within 180 days, but it didn't take that long for Chavez DeRemer to hint that her conclusion will be in favor of private equity.
'The federal government should not be making retirement investment decisions for hardworking Americans, including decisions regarding alternative assets,' she said in a statement shortly after the executive order was signed, adding that the order supports efforts to 'eliminate unfair one-size-fits-all approaches' to retirement investing.
Private equity firms that have been clamoring for looser regulations ever since Trump reclaimed the presidency are finally getting their wish, following a springtime marked by tariff-fueled uncertainty that slowed dealflow and fundraising efforts. Most of the biggest players in private equity have been laying the groundwork to court more retail investors all year—Blackstone teamed up with Vanguard and Wellington Management in April to develop strategies combining public and private markets, one of several partnerships that have sprouted up among blue-chip firms.
Skeptics fear that high fees and more complex investing strategies will do more harm than good to retirees. Private equity evangelists counter that with fewer companies going public in the last 20 years, diversified access to the entire market needs to include private equity, the same way index funds gave investors access to the whole stock market 50 years ago. Plus, those who have or are still earning traditional pensions have long reaped the rewards of private equity, with public pension funds allocating 23% of their portfolios to alternatives on average, while 401(k) savers haven't had the same options.
'For decades, public pension funds have invested in private assets because they deliver strong returns over the long term and are a smart, safe way to diversify retirement savings,' said Will Dunham, president and CEO of the American Investment Council, a private equity lobbying organization, in a statement echoing the language of the executive order. 'President Trump's EO is a great step that will help all Americans enjoy the same benefits of stronger returns.'
Partners Group, which launched a private equity fund aimed at the U.S. defined contribution market in 2015, has been at the forefront of lobbying the federal government since then, arguing for more protection against excessive fee lawsuits. Trump's Labor Department sent a lawyer representing the firm an information letter in 2020 expressing openness to private markets in 401(k) plans, but when Biden took office a year later, that progress was reversed.
Today, Partners Group has a modest sum of about $150 million of the firm's $174 billion in assets in its U.S. defined contribution products, Cahill says, and will have to accelerate working alongside its private equity peers to develop and market products that will be suitable for retirement accounts. Cahill stresses that the best avenue for private equity in 401(k)s is through professionally-managed target date funds or other diversified managed accounts, instead of as a separate option on a menu that individual workers choose from.
Marc Pinto, global head of private credit at Moody's, anticipates that the executive order will lead to a proliferation of products like so-called evergreen funds which offer periodic liquidity, but cautions that 'if these new investments don't live up to their promise, asset managers could face lawsuits and regulatory heat.'
Moody's has also raised concerns about blending illiquid assets with flexible withdrawal features, and it will likely take time before major retirement plan providers like Vanguard and Fidelity develop mainstream products addressing these concerns. The ideal endgame for private equity firms is to be incorporated into target date funds, which have grown to hold about $4 trillion in assets and are now the default investment option in many 401(k) plans. These funds offer daily liquidity, but proponents of private equity argue there will be ways to incorporate small allocations to illiquid alternatives without introducing excessive risk.
'Target date funds will always be daily liquid, but there is a sentiment that everything within the target date fund must also be daily liquid, and I think that will evolve,' says Cahill. 'These funds have smart managers who have been managing portfolios for a long time. They'll know exactly what they can access and what's best to access at the right times.'
More from Forbes Forbes Inside Private Equity's $29 Trillion Retirement Savings Grab By Hank Tucker Forbes Blackstone's $80 Trillion Opportunity By Sergei Klebnikov Forbes Inside Robinhood's Crypto-Fueled Plan For World Domination By Nina Bambysheva
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Yahoo

time7 minutes ago

  • Yahoo

Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合

If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today
If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today

Yahoo

time7 minutes ago

  • Yahoo

If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today

Key Points Palantir's AIP contributed to accelerated revenue growth. Its growth has led to a pricey valuation, making its near-term direction less certain. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock has been on a tear since last year's U.S. presidential election. Since the election on Nov. 5, the stock is up by about 250%. While that is a considerable return, it is relatively modest compared to how the stock has performed over the last three years, when the market and Palantir were in the middle of a bear market. Amid the rising popularity of AI and its productivity solution, Palantir's returns since that time are nothing short of eye-popping. Palantir over the last three years If one had bought Palantir on Aug. 8, 2022, a $1,000 investment would be worth about $15,700 today. Three years ago, a dramatic pullback from the highs of the 2021 bull market left Palantir trading below $10 per share, the approximate level where it sold on its first day of trading on Sept. 30, 2020. Additionally, it got off to a slow start as it briefly fell below $6 per share in December 2022. Nonetheless, Palantir began moving higher in 2023, particularly after Open AI's release of an upgraded version of ChatGPT put the spotlight on generative AI. Palantir responded with its own generative AI solution, the artificial intelligence platform (AIP), in April 2023. Customers began reporting massive productivity gains. Over time, the stock's growth accelerated as revenue growth began to rise at a significantly faster rate. Consequently, the stock reached stratospheric highs, with a P/E ratio approaching 600. Although such earnings multiples can be common with growth stocks, its price-to-sales (P/S) ratio of 130 all but verifies that the market has priced the stock for perfection. That increases the odds of a dramatic fall at the slightest hint of bad news. However, few can deny the success of Palantir's investors over the last three years. Even if its near-term prospects are less clear, Palantir should succeed long term, since its tools have delivered massive productivity gains for its customers. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store